{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:07:45Z","timestamp":1789592865937,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.pupt.2021.102056","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T01:55:38Z","timestamp":1626314138000},"page":"102056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial"],"prefix":"10.1016","volume":"70","author":[{"given":"Nisa","family":"Laohapojanart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaveewan","family":"Ratanajamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamon","family":"Kawkitinarong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-2276","authenticated-orcid":false,"given":"Teerapol","family":"Srichana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9387","key":"10.1016\/j.pupt.2021.102056_bib1","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","volume":"362","author":"Frieden","year":"2003","journal-title":"Tuberculosis. Lancet."},{"issue":"2","key":"10.1016\/j.pupt.2021.102056_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.pupt.2021.102056_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2010.08.009","article-title":"Inhaled drug therapy for treatment of tuberculosis","volume":"91","author":"Misra","year":"2011","journal-title":"Tuberculosis"},{"issue":"11","key":"10.1016\/j.pupt.2021.102056_bib4","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","article-title":"Inhaled drug delivery for tuberculosis therapy","volume":"26","author":"Muttil","year":"2009","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"7","key":"10.1016\/j.pupt.2021.102056_bib5","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms12074414","article-title":"Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies","volume":"12","author":"Rojanarat","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.pupt.2021.102056_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/10717544.2012.721144","article-title":"Inhaled pyrazinamide proliposome for targeting alveolar macrophages","volume":"19","author":"Rojanarat","year":"2012","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.pupt.2021.102056_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/10611860903079462","article-title":"Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages","volume":"17","author":"Changsan","year":"2009","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.pupt.2021.102056_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics4030385","article-title":"Levofloxacin-proliposomes: opportunities for use in lung tuberculosis","volume":"4","author":"Rojanarat","year":"2012","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pupt.2021.102056_bib9","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.pupt.2021.102056_bib10","first-page":"1209","article-title":"Dry powder inhaler formulation","volume":"50","author":"Telko","year":"2005","journal-title":"Respir. Care"},{"issue":"13\u201314","key":"10.1016\/j.pupt.2021.102056_bib11","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.addr.2013.07.020","article-title":"Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases","volume":"65","author":"Andrade","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.pupt.2021.102056_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1567201811666140716123050","article-title":"Inhaled dry powder formulations for treating tuberculosis","volume":"12","author":"Das","year":"2015","journal-title":"Curr. Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.pupt.2021.102056_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijpharm.2018.08.061","article-title":"High dose dry powder inhalers to overcome the challenges of tuberculosis treatment","volume":"550","author":"Momin","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.pupt.2021.102056_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/1061186X.2018.1455842","article-title":"Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need","volume":"27","author":"Patil","year":"2019","journal-title":"J. Drug Target."},{"issue":"11","key":"10.1016\/j.pupt.2021.102056_bib15","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1248\/bpb.b16-00354","article-title":"Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs","volume":"39","author":"Srichana","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.pupt.2021.102056_bib16","series-title":"Tuberculosis\u00a0: Twenty-First Century Books","first-page":"58","article-title":"Diagnosis and treatment","author":"Yaney","year":"2007"},{"issue":"2","key":"10.1016\/j.pupt.2021.102056_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/dkg343","article-title":"Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines","volume":"52","author":"Sato","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.pupt.2021.102056_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkp237","article-title":"Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance","volume":"64","author":"Bergval","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.pupt.2021.102056_bib19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/AAC.32.7.1002","article-title":"Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method","volume":"32","author":"Salfinger","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"issue":"76","key":"10.1016\/j.pupt.2021.102056_bib21","first-page":"23191","article-title":"Protection of human subjects; Belmont Report: notice of report for public comment","volume":"44","year":"1979","journal-title":"Fed. Regist."},{"key":"10.1016\/j.pupt.2021.102056_bib22","unstructured":"Guideline for Good Clinical Practice. ICH harmonised tripartite guideline. E6(R1). Current step 4 version, dated 10 June 1996. (including the post step 4 corrections). The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). [Internet]. [cited 2019 Jul 27]. Available from: http:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js22154en\/."},{"issue":"2","key":"10.1016\/j.pupt.2021.102056_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/0022-3859.132311","article-title":"Reference values for peak expiratory flow in Indian adult population using a European Union scale peak flow meter","volume":"60","author":"Kodgule","year":"2014","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.pupt.2021.102056_bib24","series-title":"British Pharmacopoeial Commission","year":"2008"},{"issue":"4","key":"10.1016\/j.pupt.2021.102056_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"issue":"1","key":"10.1016\/j.pupt.2021.102056_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.pupt.2021.102056_bib27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0169-409X(02)00159-X","article-title":"Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy","volume":"54","author":"Garcia-Contreras","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.pupt.2021.102056_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fphar.2020.00333","article-title":"Both pharmacokinetic variability and granuloma heterogeneity impact the ability of the first-line antibiotics to sterilize tuberculosis granulomas","volume":"11","author":"Cicchese","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.pupt.2021.102056_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijpharm.2018.08.061","article-title":"High dose dry powder inhalers to overcome the challenges of tuberculosis treatment","volume":"550","author":"Momin","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.pupt.2021.102056_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cell.2020.02.026","article-title":"Mycobacterium tuberculosis sulfolipid-1 activates nociceptive neurons and induces cough","volume":"181","author":"Ruhl","year":"2020","journal-title":"Cell"},{"issue":"Suppl 7","key":"10.1016\/j.pupt.2021.102056_bib31","first-page":"S708","article-title":"Effect of viral upper respiratory tract infection on cough reflex sensitivity","volume":"6","author":"Dicpinigaitis","year":"2014","journal-title":"J. Thorac. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2021.102056_bib32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.pupt.2013.02.003","article-title":"Mucous hypersecretion and relationship to cough","volume":"26","author":"Nadel","year":"2013","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.pupt.2021.102056_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2213-2600(16)30433-7","article-title":"Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.pupt.2021.102056_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s12879-014-0547-7","article-title":"A retrospective review of a tertiary Hospital's isolation and de-isolation policy for suspected pulmonary tuberculosis","volume":"14","author":"Kalimuddin","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"7","key":"10.1016\/j.pupt.2021.102056_bib35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/thx.53.7.536","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998","volume":"53","year":"1998","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.pupt.2021.102056_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"issue":"7","key":"10.1016\/j.pupt.2021.102056_bib37","first-page":"346","article-title":"Effect of antituberculous drugs on serum uric acid and urine uric acid excretion","volume":"21","author":"Louthrenoo","year":"2015","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1016\/j.pupt.2021.102056_bib38","series-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","year":"2019"},{"issue":"37","key":"10.1016\/j.pupt.2021.102056_bib39","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.pupt.2021.102056_bib40","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pupt.2021.102056_bib41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.addr.2007.08.023","article-title":"In vivo animal models for drug delivery across the lung mucosal barrier","volume":"59","author":"Cryan","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.pupt.2021.102056_bib42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jps.2600770413","article-title":"Drugs administered directly into the respiratory tract:Modeling of the duration of effective drug levels","volume":"77","author":"Gonda","year":"1988","journal-title":"J. Pharmaceut. Sci."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:16Z","timestamp":1761082216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553921000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":41,"alternative-id":["S1094553921000687"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102056","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102056"}}